WHO R&D Blueprint

novel Coronavirus

COVID-19 Animal Models

WHO Working Group
Table of Contents

TABLE OF CONTENTS ................................................................................................................. 2
BACKGROUND ............................................................................................................................. 3
TERMS OF REFERENCE ............................................................................................................... 3
COMPOSITION............................................................................................................................ 3
  EXPERTS ................................................................................................................................. 3
  WHO SECRETARIAT ............................................................................................................... 7
Background

In response to the current COVID-19 pandemic, the WHO Blueprint team has established an ad hoc Expert Group focused on COVID-19 disease modelling (WHO-COM). The goal of the disease modelling group is to advance the development of COVID-19 medical countermeasures (vaccines, therapeutics and/or drugs). This is being achieved by providing a platform to share data to help reduce duplication of effort and to accelerate learning by sharing outcomes in a secure and confidential workspace. In addition, the principles of reduction, refinement and replacement are being addressed by this international effort.

Terms of Reference

- Review progress towards the identification of animal models for testing COVID-19 vaccines and therapeutics.
- Coordinate preclinical studies to ensure data reproducibility and to avoid effort duplication.
- Identify gaps in knowledge about COVID-19 pathophysiology and immunity. Ensure data sharing across group members to facilitate the identification of disease biomarkers and correlates of immunity.
- Coordinate efforts with other WHO groups focused on COVID-19 control and development of medical countermeasures.
- Accelerate a vaccine assessment pathway to guide how global resources should be applied to the current COVID-19 global response

Composition

Experts

Chairs:
Dr. William Dowling, CEPI; Dr. Simon Funnell, PHE and Dr. César Muñoz-Fontela, BNITM.

The chairs have the following responsibilities
- To chair the weekly meetings
- To liaise with the WHO R&D Blueprint
- To review meeting reports and reports from any interim recommendations
- To represent the WHO-COM at technical meetings as requested

Members:
Sandra Cordo, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
Jin Zhu, Australian Government Department of Health, Australia
Terms of Reference
WG established on February 2020

Pearl Bamford, Australian Government Department of Health, Australia
Vasan Vasan, CSIRO, Australia
Kanta Subbarao, Doherty Institute, Australia
Kevin Alyson, Dalhousie University, Canada
Darwyn, Kobasa, Public Health Agency of Canada (PHAC), Canada.
Jason Kindrachuk, University Manitoba, Canada
Gary Kobinger, Universite Laval, Canada
Dave O’Connor, University of Wisconsin, Canada
Darryl Falzarano, Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO-Intervac), University of Saskatchewan, Canada
Paul Hodgson, Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO-Intervac), University of Saskatchewan, Canada
Volker Gerds, Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO-Intervac), University of Saskatchewan, Canada
Chuan Qin, Peking Union Medical College, China
Chao Shan, Wuhan Institute of Virology, Chinese Academy of Sciences, China
Marco Cavaleri, European Medicine Agency
Romain Volmer, Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail (ANSES), France.
Sandrine Lesellier, Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail (ANSES), France.
Christiane Gerke, Institut Pasteur, France
Pauline Maissonaise, Vaccine Research Institute, France
Roger Le-Grand, Vaccine Research Institute, France
Estefania Rodriguez-Burgos, Bernhard Nocht Institute for Tropical Medicine (BNITM), Germany
Barbara Schnierle, Paul Ehrlich Institute, Germany
Bernhard Kerscher, Paul Ehrlich Institute, Germany
Harry Kleanthous, Bill and Melinda Gates Foundation, USA
Amy Shurtleff, Coalition for Epidemic Preparedness Innovations (CEPI), Norway.
Carolyn Clark, Coalition for Epidemic Preparedness Innovations (CEPI), Norway.
Honglin Chen, Hong Kong University (HKU), China
Jasper Chan, Hong Kong University (HKU), China
Noriyo Nagata, Japanese National Institute of Infectious Diseases, Japan
Tadaki Suzuki, Japanese National Institute of Infectious Diseases, Japan
Denis Logunov, Gamaleya Institute, Russian Federation
Igor Krasilnikov, St. Petersburg Scientific Research Institute of Vaccines and Serums, Russian Federation
Sergey Arakelov, St. Petersburg Scientific Research Institute of Vaccines and Serums, Russian Federation.
Yuri Vasiliev, St. Petersburg Scientific Research Institute of Vaccines and Serums, Russian Federation.
LinFa Wang, Duke-National University of Singapore, Singapore
Seong-Jun Kim, Center for Convergent Research of Emerging Virus Infection, Republic of Korea
Kim Seungtaek, Institut Pasteur, Republic of Korea
Manki Song, International Vaccine Institute, Republic of Korea
Je Kyung Seong, Korea Mouse Phenotyping Center, Republic of Korea
Luis Enjuanes, Comisión Nacional de Biotecnología (CNB)-CSIC, Spain
Ali Mirazimi, Karolinska Institute, Sweden
Paul Lambert, University Geneva, Switzerland
Barry Rockx, Erasmus MC- Viroscience (EMC), The Netherlands
Bart Haagmans, Erasmus MC, Centre for Infectious Disease Control (RIVM) - Viroscience (EMC), The Netherlands
Jorgen De Jonge, National Institute of Public Health and the Environment (RIVM), The Netherlands
Koert Stittelaar, Viroclinics, The Netherlands
Jeroen Kortekaas, Wageningen University, The Netherlands
Nadia Oreshkova, Wageningen University, The Netherlands
Nora Gerhards, Wageningen University, The Netherlands
Jo Prior, Defence Science and Technology (dstl), United Kingdom
Michelle Nelson, Defence Science and Technology (dstl), United Kingdom
Rachel Ireland, Defence Science and Technology (dstl), United Kingdom
Steve Lever, Defence Science and Technology (dstl), United Kingdom
Neil Berry, National Institute for Biological Standards and Control (NIBSC), United Kingdom
Nicola Rose, National Institute for Biological Standards and Control (NIBSC), United Kingdom
Giada Mattiuzzo, National Institute for Biological Standards and Control (NIBSC), United Kingdom
Mark Page, National Institute for Biological Standards and Control (NIBSC), United Kingdom
Nicola Rose, National Institute for Biological Standards and Control (NIBSC), United Kingdom
Julia Tree, Public Health England (PHE), United Kingdom
Miles Carroll, Public Health England (PHE), United Kingdom
Yper Hall, Public Health England (PHE), United Kingdom
James Stewart, University of Liverpool, United Kingdom
James Little, Biomedical Advanced Research and Development Authority (BARDA), United States of America
John Treanor, Biomedical Advanced Research and Development Authority (BARDA), United States of America
Lakshmi Jayashankar, Biomedical Advanced Research and Development Authority (BARDA), United States of America
Ruben Donis, Biomedical Advanced Research and Development Authority (BARDA), United States of America
Carol Sabourin, Biomedical Advanced Research and Development Authority (BARDA), United States of America
Karl Erlandson, Biomedical Advanced Research and Development Authority (BARDA), United States of America
Terms of Reference
WG established on February 2020

Gloria Sivko, Battelle, United States of America
Mark Lewis, Bioqual; United States of America
Monalisa Chatterji, BMGF, United States of America
David Vaughn, Bill and Melinda Gates Foundation, BMGF, United States of America
Jacqueline Kirchner, Bill and Melinda Gates Foundation (BMGF), United States of America
Karen Makar, Bill and Melinda Gates Foundation (BMGF), United States of America
Antony Griffiths, Boston University School of Medicine, United States of America
Natalie Thornbug, Centers for Disease Control and Prevention (CDC), United States of America
Angela Bosco-Lauth, Colorado State University, United States of America
Angela Rasmussen, Columbia University, United States of America
Sina Bavari, Edge Bioinnovation Consulting and Management, United States of America
Paul Duprex, Center for Vaccine Research (CVR) Pittsburgh, United States of America
JoAnne Flynn, Center for Vaccine Research (CVR) Pittsburgh, United States of America
Alexander White, Center for Vaccine Research (CVR) Pittsburgh, United States of America
Renee Wegrzyn, Defense Advanced Research Projects Agency (DARPA), United States of America.
Geraldine Hamilton, EmulateBio, United States of America
Hana Golding, Food and Drug Administration, United States of America
Tony Wang, Food and Drug Administration, United States of America
Tracy MacGill, Food and Drug Administration, United States of America
Phil Krause, Food and Drug Administration, CBER, United States of America
Robin Levis, Food and Drug Administration, CBER, United States of America
Dan Barouch, Harvard University, United States of America
Florian Krammer, Icahn School of Medicine at Mount Sinai, United States of America
Juergen Richt, Kansas State University, United States of America
David Revelli, Lovelace Biomedical, United States of America
Chi Van Dang, Ludwig Institute for Cancer Research, United States of America
Adolfo Garcia-Sastre, Mount Sinai, United States of America
Randy Albrecht, Mount Sinai, United States of America
Clint Florence, National Institute of Allergy and Infectious Diseases (NIAID) - DMID, United States of America
Erik Stemmy, National Institute of Allergy and Infectious Diseases (NIAID) - DMID, United States of America
Chelsea Lane, National Institute of Allergy and Infectious Diseases (NIAID) - DMID, United States of America
Thames Pickett, National Institute of Allergy and Infectious Diseases (NIAID) - DMID, United States of America
Connie Schmaljohn, National Institute of Allergy and Infectious Diseases (NIAID) - IRF, United States of America
Lisa Hensley, National Institute of Allergy and Infectious Diseases (NIAID) - IRF, United States of America
Terms of Reference

WG established on February 2020

Mike Holbrook, National Institute of Allergy and Infectious Diseases (NIAID) - IRF, United States of America
Ian Crozier, National Institute of Allergy and Infectious Diseases (NIAID) - IRF, United States of America
Emmie De Wit, National Institute of Allergy and Infectious Diseases (NIAID) - RML, United States of America
Vincent Munster, National Institute of Allergy and Infectious Diseases (NIAID) - RML, United States of America
Barney Graham, National Institute of Allergy and Infectious Diseases (NIAID) - VRC, United States of America
Sheri Hild, National Institute of Health (NIH), United States of America
Fred Cassels, PATH, United States of America
Jonathan Spergel, Perelman School of Medicine, University of Pennsylvania, United States of America
Fusataka Koide, Southern Research, United States of America
Ricardo Carrion, Texas Biomed Research Institute, United States of America
David Lee-Paritz, Tufts Cummings School of Veterinary Medicine, United States of America
Chad Roy, Tulane University, United States of America
Ralph Baric, UNC Gillings School of Public Global Public Health, United States of America
Doug Reed, University of Pittsburgh, United States of America
Erik Dohm, University of Alabama, United States of America
Samuel Cartner, University of Alabama, United States of America
Stanley Perlman, University of Iowa, United States of America
Thomas Friedrich, University of Wisconsin, United States of America
Gustavo Palacios, United States Army Medical Institute of Infectious Diseases (USAMRIID), United States of America
Aysegul Nalca, United States Army Medical Institute of Infectious Diseases (USAMRIID), United States of America
Louise Pitt, United States Army Medical Institute of Infectious Diseases (USAMRIID), United States of America
Grace Lidl, United States Army Medical Institute of Infectious Diseases (USAMRIID), United States of America
Christian Hofer, United States Army Medical Institute of Infectious Diseases (USAMRIID), United States of America
Ken Tseng, The University of Texas Medical Branch (UTMB), United States of America
Trevor Brasel, The University of Texas Medical Branch (UTMB), United States of America
Melissa Eitzen, The University of Texas Medical Branch (UTMB), United States of America
Kayvon Modjarrad, Walter Reed Army Institute of Research, United States of America

WHO Secretariat

Ana Maria Henao-Restrepo, Pierre Gsell, Ximena Riveros, David Wood